Adeza to Present at Needham & Company's Fifth Annual Biotechnology and Medical Technology Conference; Webcast Scheduled Thursda
2006年6月8日 - 5:00PM
ビジネスワイヤ(英語)
Adeza (NASDAQ:ADZA) today announced that Emory V. Anderson,
president and chief executive officer, will make an investment
community presentation at the Needham & Company, LLC's Fifth
Annual Biotechnology and Medical Technology Conference on Thursday,
June 15 at 3:30 p.m. Eastern time (12:30 p.m. Pacific time). The
conference is being held at the New York Palace Hotel. A live audio
and slide webcast of the presentation will be available via the
Internet by visiting the company's Web site at www.adeza.com. An
archived presentation will be available on the Web site for 14
days. Adeza designs, manufactures and markets innovative products
for women's health. Adeza's initial focus is on reproductive
healthcare using its proprietary technologies to predict preterm
birth and assess infertility. Adeza's principal product is a
patented diagnostic test, FullTerm(TM), The Fetal Fibronectin Test,
which utilizes a single-use, disposable cassette and is analyzed on
Adeza's patented TLiIQ(R) System. This product is approved by the
U.S. Food and Drug Administration (FDA) for use in assessing the
risk of preterm birth. Adeza also markets and sells the
E-tegrity(R) Test, an infertility-related test to assess
receptivity of the uterus to embryo implantation in women with
unexplained infertility. In May 2006, Adeza announced the
submission of a New Drug Application (NDA) with the FDA for
Gestiva, a long-acting form of a naturally occurring progesterone
to prevent preterm birth in women with a history of preterm
delivery. Adeza's NDA submission includes data from a clinical
study conducted by the National Institutes of Health. More
information is available at www.adeza.com. Adeza cautions you that
statements included in this press release that are not a
description of historical facts may be forward-looking statements.
The inclusion of forward-looking statements should not be regarded
as a representation by Adeza that any of its plans will be
achieved. Actual results may differ materially from those set forth
in this release due to the risks and uncertainties inherent in
Adeza's business including, without limitation, statements about
the expansion of the indications for its products. Further
information about these and other risks is included in Adeza's
Annual Report on Form 10-K and other periodic and current reports
filed by Adeza with the Securities Exchange Commission, which are
available from the SEC's Web site (www.sec.gov), and also available
on the Investor Relations section of Adeza's Web site. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Adeza undertakes no obligation to revise
or update this news release to reflect events or circumstances
after the date hereof.
Adeza (NASDAQ:ADZA)
過去 株価チャート
から 8 2024 まで 9 2024
Adeza (NASDAQ:ADZA)
過去 株価チャート
から 9 2023 まで 9 2024
Real-Time news about Adeza Biomedical (MM) (ナスダック市場): 0 recent articles
その他のAdezaニュース記事